Millennium Pharmaceuticals
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (March 2008) |
| Millennium Pharmaceuticals, Inc. | |
|---|---|
 |
|
| Type | Public (NYSE:MLNM) |
| Founded | 1993 |
| Headquarters | Cambridge, MA, USA |
| Key people | Deborah Dunsire, M.D., President & CEO |
| Industry | Biotechnology, Pharmaceutical Company |
| Products | Velcade (bortezomib) for injection |
| Employees | 965 (approx.) |
| Website | http://www.millennium.com/ |
Millennium Pharmaceuticals, Inc. NASDAQ: MLNM is a biopharmaceutical company based in Cambridge, Massachusetts. The Company markets Velcade (bortezomib) for injection, a cancer product, and has a growing clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease, but none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.[1]
Contents |
[edit] History
Millennium was founded in 1993. In its early years, Millennium focused on building science and business teams. Beginning in 1994, Millennium created more than 20 strategic alliances with leading pharmaceutical and biotechnology companies. These alliances provided Millennium with close to $2 billion of committed funding that was used to develop and enhance its pipeline.
A merger with Leukosite in 1999 brought the company its first drug close to market, Campath (alemtuzumab) Injection, and additional investigational drugs in clinical trials. In 2000, a merger with Cambridge Discovery Chemistry gave Millennium a strong presence in the United Kingdom and added to the organization more than 100 scientists with expertise in chemistry. In a strategic business decision, Campath was later sold to the Millennium partner for the drug, ILEX Oncology, which in turn was acquired by Genzyme.
In February 2002, there was a further merger with COR Therapeutics — among the largest such mergers in the history of the biotech industry at that time. In addition to creating a strong pipeline of novel therapeutics, the merger added cardiovascular research and drug development to the Company's other key therapeutic areas: oncology and inflammation. The merger also brought Integrilin (eptifibatide) Injection, an intravenous anti-platelet drug for patients with severe cardiovascular diseases, into the Millennium fold. Millennium partnered with Schering-Plough on the development and marketing of Integrilin until 2005 when Millennium licensed the exclusive U.S. commercialization and development rights of Integrilin to Schering-Plough.
In May 2003 Velcade was launched for the treatment of relapsed and refractory multiple myeloma – a cancer of the blood. Velcade is now approved in the U.S. for treatment of multiple myeloma patients after one prior therapy. Velcade — the first U.S. Food and Drug Administration (FDA) approved proteasome inhibitor — reached the market in record time and represented the first treatment in more than a decade to be approved for patients with multiple myeloma.
In late December 2007, Millennium successfully submitted a supplemental new drug application (sNDA) to the FDA for Velcade for previously untreated multiple myeloma. The sNDA submitted to the FDA for this indication included data from the Phase III VISTA.[2] study, a large, well-controlled international clinical trial, comparing a Velcade based regimen to a traditional standard of care. Priority review was granted by the FDA in January 2008.
[edit] Products
| Brand Name | Drug Name(s) | Indication | Date Approved (USA)[3] | Partner |
|---|---|---|---|---|
| Velcade | bortezomib | Velcade is indicated for the treatment of patients with multiple myeloma who have received at least 1 prior therapy and for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. | 05-13-2003 | Ortho Biotech and Janssen-Cilag, members of the Johnson & Johnson Family of Companies, are responsible for commercialization of Velcade in Europe and the rest of the world. |
Velcade is the first oncology drug marketed and promoted by Millennium. Velcade was granted FDA approval little more than four and a half years after initiation of the first clinical trial. To discover and develop such treatments, the Company focuses on key molecular pathways that play crucial roles in underlying disease processes, and on identifying therapeutically significant differences that may exist among people. Millennium applies this approach broadly throughout its R&D program to develop novel treatments not just for cancer but also for a number of other important diseases.
Velcade is being co-developed by Millennium Pharmaceuticals. and Johnson & Johnson Pharmaceutical Research & Development. Millennium is responsible for commercialization of Velcade in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech. are co- promoting Velcade in the U.S. Approved in 85 countries, at least 85,000 patients have been treated with Velcade globally.
[edit] References
- ^ "Shift Seen Atop Millennium Pharmaceuticals", New York Times, 2005-06-29. Retrieved on 2008-02-23.
- ^ VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone. Millennium Corporate Communications. Retrieved on 2008-03-05.
- ^ FDA Approves VELCADE. FDA. Retrieved on 2008-03-05.
